H. Tan

发表

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

B. Strober, K. Papp, R. Langley, 2013, CPT: Pharmacometrics & Systems Pharmacology.

Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole

R. Gerber, J. Cappelleri, T. Luger, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis

K. Papp, H. Valdez, S. Tyring, 2015, BMC Dermatology.

Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.

B. Strober, A. Qureshi, H. Valdez, 2016, Journal of the American Academy of Dermatology.

Quantitative Evaluations of Time‐Course and Treatment Effects of Systemic Agents for Psoriasis: A Model‐Based Meta‐Analysis

L Puig, S. Ahadieh, H. Valdez, 2017, Clinical pharmacology and therapeutics.

Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials†

B. Strober, H. Valdez, P. V. D. van de Kerkhof, 2018, The British journal of dermatology.

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

S. Chimenti, H. Valdez, F. Valenzuela, 2015, The Lancet.

Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial

L. Iversen, H. Valdez, P. Foley, 2015, The British journal of dermatology.

Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States

A. Armstrong, M. Kaur, H. Tan, 2017, Clinical Drug Investigation.

Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan Data

A. Armstrong, M. Kaur, H. Tan, 2016, Dermatology and Therapy.

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure

Stanley B. Cohen, B. Sands, K. Papp, 2021, RMD Open.

T‐cell–mediated immune response to pneumococcal conjugate vaccine (PCV‐13) and tetanus toxoid vaccine in patients with moderate‐to‐severe psoriasis during tofacitinib treatment

H. Valdez, K. Winthrop, M. Kaur, 2018, Journal of the American Academy of Dermatology.

Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.

J. D. Clark, H. Valdez, M. Suárez-Fariñas, 2016, The Journal of allergy and clinical immunology.

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo‐controlled dose‐ranging study

B. Strober, A. Menter, K. Papp, 2012, The British journal of dermatology.

Tofacitinib (CP‐690,550), an oral Janus kinase inhibitor, improves patient‐reported outcomes in a phase 2b, randomized, double‐blind, placebo‐controlled study in patients with moderate‐to‐severe psoriasis

A. Menter, H. Tan, J. Harness, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.

A. Menter, K. Papp, S. Tyring, 2014, Journal of drugs in dermatology : JDD.

Herpes zoster in psoriasis patients treated with tofacitinib

M. Lebwohl, Kaori Ito, H. Valdez, 2017, Journal of the American Academy of Dermatology.

Comparative Assessment of PASI and Variations of PGA×BSA as Measures of Psoriasis Severity

J. Walsh, H. Valdez, K. Duffin, 2017 .

Tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: long‐term safety and efficacy in an open‐label extension study

H. Valdez, R. Bissonnette, F. Valenzuela, 2018, The British journal of dermatology.

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups

M. Lebwohl, A. Paller, A. Alexis, 2019, American Journal of Clinical Dermatology.

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years

J. Silverberg, T. Luger, A. Hebert, 2022, Pediatric Drugs.

Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment

B. Strober, H. Valdez, K. Papp, 2013, The British journal of dermatology.

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study

H. Valdez, C. Paul, F. Valenzuela, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis

H. Tan, V. Purohit, W. Ports, 2020, Journal of clinical pharmacology.

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.

Robert Wolk, Steven R Feldman, James G Krueger, 2016, Journal of the American Academy of Dermatology.

Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis

C. Griffiths, H. Valdez, K. Gordon, 2017, The Journal of dermatological treatment.

Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.

J. Wohlrab, K. Papp, H. Valdez, 2016, Journal of drugs in dermatology : JDD.

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

C. Griffiths, M. Bachinsky, L. Mallbris, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

A case study of model‐based Bayesian dose response estimation

Jonathan French, Neal Thomas, Huaming Tan, 2011, Statistics in medicine.

Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight

H. Valdez, C. Mebus, K. Papp, 2017, CPT: pharmacometrics & systems pharmacology.

Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis

R. Gerber, J. Cappelleri, T. Luger, 2017 .

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area

J. Silverberg, R. Gerber, H. Tan, 2020, Acta dermato-venereologica.

Assessment of pruritus in atopic dermatitis: validation of the Severity of Pruritus Scale (SPS)

R. Gerber, J. Cappelleri, T. Luger, 2018, Itch.

Effect of crisaborole topical ointment, 2%, on atopic dermatitis–associated pruritus: an extended analysis of 2 phase 3 clinical trials

R. Gerber, J. Cappelleri, T. Luger, 2018, Itch.

Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.

J. D. Clark, H. Valdez, M. Suárez-Fariñas, 2016, The Journal of allergy and clinical immunology.